SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia

Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D. R., Dittmar, K., Kolitz, J. E., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,634

Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage

Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H., & Schlossman, S. F. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1588 · Cited by 1,629

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR

Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,172

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983

Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells

Terstappen, L. W. M. M., Huang, S., Safford, M., Lansdorp, P., & Loken, M. R. (1991) · Blood · doi:10.1182/blood.v77.6.1218.1218 · Cited by 845

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease

Hamblin, T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z. A., Thomas, P., Stevenson, F. K., & Oscier, D. G. (2002) · Blood · doi:10.1182/blood.v99.3.1023 · Cited by 618

Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma

Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4tb90buwh27jx · Cited by 454

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

Ibrahim, S., Keating, M. J., Do, K.-A., O'Brien, S. M., Huh, Y. O., Jilani, I. B., Lerner, S. A., Kantarjian, H. M., & Albitar, M. X. (2001) · Blood · doi:10.1182/blood.v98.1.181 · Cited by 451

CD38 and CD157: A long journey from activation markers to multifunctional molecules

Quarona, V., Zaccarello, G., Chillemi, A., Brunetti, E., Singh, V. K., Ferrero, E., Funaro, A., Horenstein, A. L., & Malavasi, F. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21092 · Cited by 269

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Vosoughi, T., Bagheri, M., Hosseinzadeh, M., Ehsanpour, A., Davari, N., & Saki, N. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28724 · Cited by 11

Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA

Beksaç, M., Špıčka, I., Hájek, R., Bringhen, S., Jelı́nek, T., Martin, T., Mikala, G., Moreau, P., Symeonidis, A. S., Rawlings, A. M., et al. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106948 · Cited by 11

Tumor-forming plasmacytoid dendritic cells in acute myelocytic leukemia: a report of three cases and literature review.

Wang, P., Feng, Y., Deng, X., Liu, S., Qiang, X., Gou, Y., Li, J., Yang, W., Peng, X., & Zhang, X. (2017) · PubMed Central · Cited by 11

Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma

Thoren, K. L., Menad, S., Nouadje, G., & Macé, S. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae028 · Cited by 10

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment

Dimopoulos, M. A., Mikhael, J. R., Terpos, E., Leleu, X. P., Moreau, P., Bladé, J., Kim, J. S., Stockerl-Goldstein, K. E., & Richardson, P. G. G. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221088458 · Cited by 10

Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic

Morgan, G. J., & Rasche, L. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1489718 · Cited by 10

Antiplasma cell antibodies: A new era of human leukocyte antigen antibody control in solid organ transplantation

Chandran, S., & Vincenti, F. G. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.10.005 · Cited by 9

Rational Design and Identification of Small‐Molecule Allosteric Inhibitors of CD38

Yang, L., Li, T., Li, S., Wu, Y., Shi, X., Jin, H., Liu, Z., Zhao, Y. J., Zhang, L., Lee, H. C., et al. (2019) · ChemBioChem · doi:10.1002/cbic.201900169 · Cited by 9

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

Carlo‐Stella, C., Zinzani, P. L., Sureda, A. M., Araújo, L. F., Casasnovas, O., Carpio, C. D. C., Yeh, S., Bouabdallah, K. K., Cartron, G., Kim, W. S., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3089 · Cited by 9

Antibody therapies for multiple myeloma

Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., & Terpos, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1717464 · Cited by 9

Monoclonal antibodies as an addition to current myeloma therapy strategies

Jullien, M., Touzeau, C., & Moreau, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1837627 · Cited by 10

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment

Morè, S., Petrucci, M. T., Corvatta, L., Fazio, F., Offidani, M., & Olivieri, A. (2020) · Pharmaceuticals · doi:10.3390/ph13120426 · Cited by 9

Immunotherapy in AL Amyloidosis

Zhang, Y., & Comenzo, R. L. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00922-4 · Cited by 9

Treatment of Relapsed/Refractory Multiple Myeloma

Neri, P. E., Bahlis, N. J., Paba‐Prada, C. E., & Richardson, P. G. G. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_10 · Cited by 10

Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma

Podar, K., & Pecherstorfer, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340942 · Cited by 9

Single–amino acid variants in target epitopes can confer resistance to antibody-based therapies

Marone, R., Asllanaj, E., Capoferri, G., Schwede, T. F., Jeker, L. T., & Lepore, R. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ady4877 · Cited by 11

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Gay, F., Roeloffzen, W., Dimopoulos, M. A., Rosiñol, L., van der Klift, M., Mina, R., Oriol, A., Katodritou, E., Wu, K. L., Rodríguez‐Otero, P., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04282-0 · Cited by 8

Cardiovascular toxicity from therapies for light chain amyloidosis

Morfino, P., Aimo, A., Castiglione, V., Chianca, M., Vergaro, G., Cipolla, C. M., Fedele, A., Emdin, M., Fabiani, I., & Cardinale, D. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1212983 · Cited by 8

Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells

Baum, N., Eggers, M., Koenigsdorf, J., Menzel, S., Hambach, J., Stähler, T., Fliegert, R., Kulow, F., Adam, G., Haag, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.703574 · Cited by 8

Radiolabeling and cytotoxicity of monoclonal antibody Isatuximab functionalized silver nanoparticles on the growth of multiple myeloma

El-Shershaby, H. M., Farrag, N. S., Ebeid, N. H., & Moustafa, K. A. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122019 · Cited by 8

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma

Steinbach, M. N., Julian, K. L., McClune, B. L., & Sborov, D. W. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221100659 · Cited by 8

Current Treatment Strategies for Multiple Myeloma at First Relapse

Mavrothalassitis, E., Triantafyllakis, K., Malandrakis, P., Gavriatopoulou, M., Kleber, M., & Ntanasis‐Stathopoulos, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051655 · Cited by 7

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies

Richardson, P. G. G., Perrot, A., Mikhael, J. R., Martin, T. G., Beksaç, M., Špıčka, I., Capra, M., D’Agostino, M., Sonneveld, P., Bisht, K. K., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01149-w · Cited by 7

The Synchronous Presence of Multiple Myelomas and Other Primary Malignant Tumors: Case Series with Literature Review

Li, N., Liu, X., Song, Y., Luo, S., & Fang, B. (2020) · Cancer Management and Research · doi:10.2147/cmar.s238288 · Cited by 7

Nanobodies as probes to investigate purinergic signaling.

Eggers, M., Ruhl, F., Haag, F., & Koch-Nolte, F. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114394 · Cited by 6

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

Richardson, P. G. G., Facon, T. T. F., Bensinger, W., Leleu, X. P., Campana, F., Macé, S., Chiron, M., de Velde, H. J. V., & Mikhael, J. R. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00438-y · Cited by 7

Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma

D’Agostino, M., Gazzera, G., Cetani, G., Bringhen, S., Boccadoro, M., & Gay, F. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180514114806 · Cited by 7

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial

Schmitt, M. W., Hückelhoven, A. G., Hundemer, M., Schmitt, A., Lipp, S., Emde, M., Salwender, H. J., Hänel, M., Weisel, K. C., Bertsch, U., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11215 · Cited by 7

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience

Mohan, M., Becnel, M., Shah, U. A., Dong, H., Gundarlapalli, S., Peterson, T., Orozco, J., Horowitz, S. B., Chhabra, S., Dhakal, B., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26580 · Cited by 6

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

Richter, J. R., Lin, P. L., García-Horton, V., Guyot, P., Singh, E., Zhou, Z., Sievert, M., & Taiji, R. (2023) · Cancer Medicine · doi:10.1002/cam4.5584 · Cited by 6

Practical Approaches to the Management of Dual Refractory Multiple Myeloma

Lee, H. C., Mark, T. M., & Shah, J. J. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0312-7 · Cited by 6

Antibody‐based immunotherapy for treatment of immunoglobulin light‐chain amyloidosis

Parrondo, R. D., Majeed, U., & Sher, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.16697 · Cited by 6

One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection

Etiève, R., Wynsberghe, M. V., Grangé, S., Laurent, C., Lemoine, M., Candon, S., Bertrand, D., & de Nattes, T. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf283 · Cited by 5

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO

Parmar, G., Capra, M., Seguro, F. S., Hungria, V., Dimopoulos, M. A., Delimpasi, S., Minařík, J., Špıčka, I., Pour, L., Marques, H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01436-0 · Cited by 5

Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions

Richardson, P. G. G., O’Donnell, E. K., O’Gorman, P., Leypoldt, L. B., Laubach, J. P., Gay, F., Leleu, X. P., Facon, T. T. F., Moreau, P., Dimopoulos, M. A., et al. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2532446 · Cited by 5

Facing lenalidomide-refractory myeloma

Cavo, M. (2019) · Blood · doi:10.1182/blood-2019-04-901157 · Cited by 5

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

Krohn, S., Boje, A. S., Gehlert, C. L., Lutz, S., Darzentas, N., Knecht, H., Herrmann, D., Brüggemann, M., Scheidig, A. J., Weisel, K. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908093 · Cited by 5

Identifying therapeutic monoclonal antibodies using target protein collision electrophoresis reflex assay to separate the wheat from the chaff

Teuwen, J. T. J., Ritzen, L. F. L., KNAPEN, Y., Ludwiczek, P. K., Damoiseaux, J. G. M. C., van Beers, J. J. B. C., & de Boer, D. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113552 · Cited by 5

Overexpression of circulating CD38+ NK cells in colorectal cancer was associated with lymph node metastasis and poor prognosis

Wang, X., Li, H., Chen, H., Fang, K., & Chang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1309785 · Cited by 5

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Tagami, N., Uchiyama, M., Suzuki, K., Shirai, H., Seto, T., Nishina, S., & Iida, S. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03800-5 · Cited by 5

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38

Li, S., Chen, D., Yang, Y., Guo, H., Liu, D., Sun, N., Bai, X., Wang, K., Li, T., Li, G., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1398508 · Cited by 5

Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients

Traxel, S., Schadt, L., Eyer, T., Mordasini, V., Gysin, C., Munthe, L. A., Niggli, F. K., Nadal, D., & Bürgler, S. (2018) · Oncogene · doi:10.1038/s41388-018-0594-4 · Cited by 5

Treatment of double-refractory multiple myeloma

Семочкин, С. В. (2021) · Oncohematology · doi:10.17650/1818-8346-2021-16-3-58-73 · Cited by 5

Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective

Horenstein, A. L., Frerichs, K. A., Faini, A. C., van de Donk, N. W. C. J., & Malavasi, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769281 · Cited by 4

Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma

Li, J., Faruque, H. A., Cortes-Sanchez, E., VanBrocklin, M. W., Hu‐Lieskovan, S., Cina, M. L., Young, A., Kopec̆ek, J., & Yang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114193 · Cited by 4

Targeting lncRNA MALAT1 attenuates lenalidomide resistance via CD38 epigenetic modulation, oxidative stress–mediated cell death, and remodeling of the pro-tumor microenvironment in multiple myeloma

Chang, W.-H., Liao, W., Yeh, T., Moi, S., Liu, Y., Hsiao, H., Wang, H., Du, J., Gau, Y., Yang, C.-I., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07252-1 · Cited by 7

An update in treatment options for multiple myeloma in nontransplant eligible patients

Broijl, A., & Sonneveld, P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1075507 · Cited by 4

EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma

Delgado, J., Zienowicz, M., van Hennik, P. B., Moreau, A., Gisselbrecht, C., Enzmann, H. G., & Pignatti, F. (2021) · The Oncologist · doi:10.1002/onco.13892 · Cited by 4

Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma

Shah, B., Gray, J., Abraham, I. L., & Chang, M. M. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221107850 · Cited by 4

Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study

Sunami, K., Fuchida, S., Suzuki, K., Ri, M., Matsumoto, M., Shimazaki, C., Asaoku, H., Shibayama, H., Ishizawa, K., Takamatsu, H., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3105 · Cited by 4

Engineered CD147-Deficient THP-1 Impairs Monocytic Myeloid-Derived Suppressor Cell Differentiation but Maintains Antibody-Dependent Cellular Phagocytosis Function for Jurkat T-ALL Cells with Humanized Anti-CD147 Antibody

Pamonsupornwichit, T., Sornsuwan, K., Juntit, O.-A., Yasamut, U., Takheaw, N., Kasinrerk, W., Wanachantararak, P., Kodchakorn, K., Nimmanpipug, P., Intasai, N., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126626 · Cited by 4

Novel and effective tandem CD38 and CD19 targeting CAR-T cells inhibit hematological tumor immune escape

Liu, X., Feng, Y., Song, Z., Liu, J., Luo, Z., Yu, G., & Wang, J. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.104950 · Cited by 4

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Steinhardt, M., Zhou, X., Krummenast, F., Meckel, K., Nickel, K., Böckle, D., Messerschmidt, J., Knorz, S., Dierks, A., Heidemeier, A., et al. (2020) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738420980258 · Cited by 4

Cellular immunity in the era of modern multiple myeloma therapy

Liu, Z., Zhao, X., Shen, H., Liu, X., Xu, X., & Fu, R. (2023) · International Journal of Cancer · doi:10.1002/ijc.34609 · Cited by 5

Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma

Ueno, T., Ohta, T., Imanaga, H., Nakazawa, M., Sato, Y., Sugio, Y., Uchida, Y., Ohno, Y., & Uehara, Y. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7509-21 · Cited by 4

Monoclonal Antibodies

Klein, C. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-876-3 · Cited by 4

Chasing optimal first-in-human (FIH) starting dose for biotherapeutics in oncology

Amara, C. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2477190 · Cited by 4

Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity

Loyau, J., Monney, T., Montefiori, M., Bokhovchuk, F. M., Streuli, J., Blackburn, M., Goepfert, A., Caro, L. N., Chakraborti, S., Angelis, S. D., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2457471 · Cited by 3

Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study

Sgherza, N., Battisti, O., Curci, P., Conticello, C., Palmieri, S., Derudas, D., Germano, C., Martino, E. A., Mele, G., Pepa, R. D., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18040595 · Cited by 3

CD38 Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma

Verina, D., Fowler, A., Louw, K., Barnes, Y., & Vickroy, A. M. (2022) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2022.05.001 · Cited by 3

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

Thai, H., Koiwai, K., Shitara, Y., Kazama, H., Fau, J., Sémiond, D., & Veyrat‐Follet, C. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12947 · Cited by 3

The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

Shimazu, Y., Kanda, J., Onda, Y., Fuchida, S., Ohta, K., Shimura, Y., Kosugi, S., Yamamura, R., Matsuda, M., Hanamoto, H., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03711-8 · Cited by 3

Anticorps anti-CD38 dans le myélome multiple

Moreaux, J. (2019) · médecine/sciences · doi:10.1051/medsci/2019198 · Cited by 3

Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) for the Management of Relapsed Multiple Myeloma

Banerjee, R. K., Lo, M., & Martin, T. G. (2021) · Future Oncology · doi:10.2217/fon-2021-0778 · Cited by 3

Antibody based immunotherapy for multiple myeloma: it’s about time

Sher, T., & Gertz, M. A. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1092530 · Cited by 3

Treatment of MM: Upcoming Novel Therapies

Lonial, S. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_11 · Cited by 3

Clinical Efficacy of Daratumumab in Monotherapy of Relapsed/Refractory Multiple Myeloma

Бессмельцев, С. С., Karyagina, E. V., Ilyushkina, E., Столыпина, Ж. Л., Рифкатовна, М. Р., Kostroma, I. I., & Шелковская, Т. Л. (2020) · Clinical oncohematology · doi:10.21320/2500-2139-2020-13-1-25-32 · Cited by 3

Impact of Human Genetic Variation Underlying Resistance to Antigen-Specific ImmunotherapyPreprint

Marone, R., Asllanaj, E., Capoferri, G., Schwede, T. F., Jeker, L. T., & Lepore, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.02.651174 · Cited by 3

Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis

Kawano, Y., Kım, K., Min, C., Koh, Y., Ishizawa, K., Kim, S. H., Ito, S., Tanaka, J., Uchiyama, M., Ishida, T., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.06.011 · Cited by 2

Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells

Kläsener, K., Herrmann, N., Håversen, L., Sundell, T., Sundqvist, M., Lundqvist, C., Manna, P. T., Jonsson, C. A., Visentini, M., Sass, D. L., et al. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.70011 · Cited by 2

Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma

Osuna‐Gómez, R., López‐Pardo, J., Mulet, M., Nomdedeu, J. F., Cantó, E., Ortín, R., Cayuela, Á. S., Ortiz, M. A., Guinart-Cuadra, A., & Vidal, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101278 · Cited by 2

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study

Baruchel, A., Nysom, K., Kang, H. J., Felice, M. S., Michalowski, M. B., Freigeiro, D. H., Epelman, S., de Sousa, A. V. L., Valera, E. T., Moreira, L., et al. (2025) · HemaSphere · doi:10.1002/hem3.70245 · Cited by 2

Discovery of Potent and Orally Bioavailable Novel Cluster of Differentiation 38 (CD38) Small Molecule Inhibitors

Shiroodi, R., Montavon, T. J., Nelson, B. M., Randolph, J. T., O’Flynn, D. E., Iu, L., Hutchins, C. W., Baikstis, T., Izquierdo, J., Smyth, D., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00171 · Cited by 2

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study

Ishida, T., Ito, S., Tanaka, J., Uchiyama, M., Kawano, Y., Moreau, P., Martin, T. G., Risse, M., Tada, K., Suzuki, K., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac137 · Cited by 2

The first relapse in multiple myeloma: how to pick the next best thing

Devarakonda, S. S., Sharma, N., & Efebera, Y. A. (2022) · Hematology · doi:10.1182/hematology.2022000356 · Cited by 2

Radionuclide Therapy of Leukemias and Multiple Myeloma

Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_48 · Cited by 2

The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease

Derudas, D., & Chiriu, S. (2024) · Pharmaceuticals · doi:10.3390/ph17081029 · Cited by 3

Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/ II data

Pitoy, A., Desmée, S., Riglet, F., Thai, H., Klippel, Z. K., Sémiond, D., Veyrat‐Follet, C., & Bertrand, J. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13206 · Cited by 2

Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma

Padda, J., Khalid, K., Zubair, U., Peethala, M. M., Kakani, V., Goriparthi, L., Almanie, A. H., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.15917 · Cited by 2

Novel Targets in Multiple Myeloma

Chari, A. (2015) · American Journal of Hematology / Oncology® · Cited by 2

Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity

Yu, T., Qiao, C., Lv, M., & Tang, L. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0524-8 · Cited by 2

Updates in the management of relapsed/refractory multiple myeloma

Hanna, K. S., Larson, S., Nguyen, J. M., Tu, S., Boudreau, J., & Rose, S. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211028906 · Cited by 2

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Sun, M. Y., Jing, H., Qu, X., Dong, F., Li, Y., Feng, Z., Ziti‐Ljajic, S., Sémiond, D., Li, L., Qi, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59186-1 · Cited by 1

Comparative efficacy of anti‐CD38 monoclonal antibodies in multiple myeloma using a network meta‐analysis

Doshi, A., Filho, J. T. D. S., Grimshaw, A. A., Giri, S., & Costa, L. J. (2025) · British Journal of Haematology · doi:10.1111/bjh.70199 · Cited by 1

PET Imaging of CD38 and IND enabling studies of [89Zr]Zr-DFO-Isatuximab

Wright, B. D., Houson, H. A., Fernandez, S., Gultekin, K., McConathy, J., Giri, S., & Lapi, S. E. (2025) · Molecular Imaging and Biology · doi:10.1007/s11307-025-02062-9 · Cited by 1

Resolving the Interference of Anti‐CD38 Antibodies on Blood Compatibility Assays Using CD38 “Baitbodies” Approach

Gnann, D. C., Steinke, S., Garritsen, H. S. P., & Hust, M. (2026) · Journal of Immunology Research · doi:10.1155/jimr/7343647 · Cited by 1

CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities

Zheng, M., Zhang, K., Mu, H., Liu, Q., Ge, S., Shan, Y., Ma, H., Peng, X., Li, S., Zhang, H., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01232 · Cited by 1

Precision targeting of CD38 in immune thrombocytopenia: Mechanistic foundations and therapeutic implications

Zhou, X., Liu, Y., Zhang, P., & Shan, N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178812 · Cited by 1

An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma

Piggin, A., & Prince, H. M. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1924052 · Cited by 1

Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma

Holstein, S. A. (2022) · Hematology · doi:10.1182/hematology.2022000335 · Cited by 1

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Fallahi, M. S., Zerangian, N., Ghorbani, A., Erabi, G., Shirali, M., Shabani, E., Rommasi, F., Najafabadi, M. M., Karbasi, S., Toutounchian, S., et al. (2023) · Current Cancer Therapy Reviews · doi:10.2174/1573394719666230201122212 · Cited by 1

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report

Ryabukhina, Y. E., Zeynalova, P. A., Abbasbeyli, F. M., Тимофеева, О. Л., Valiev, T. T., Александровна, К. Н., & Жуков, А. Г. (2023) · Oncohematology · doi:10.17650/1818-8346-2023-18-4-90-103 · Cited by 1

Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

Chen, W., You, J., Lin, L. C., Yan, X., An, G., Wang, Y., Tian, W., Ding, K., Zhang, X., Chen, W.-M., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003649 · Cited by 1

Design, synthesis, and evaluation of the effect of potential peptides against CD38: An in silico and in vitro study

Nabi‐Afjadi, M., Dabirmanesh, B., Asghari, S. M., Ramezanpour, S., Fathollahi, Y., & Khajeh, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118347 · Cited by 1

Plasma Cell Disorders

Flores-Montero, J. A., Sanoja-Flores, L., Pérez, J. J., Pojero, F., Puig, N., Vídriales, M., & Órfão, A. (2016) · ASM Press eBooks · doi:10.1128/9781555818722.ch24 · Cited by 1

Impact de CD38 dans la leucémie à tricholeucocytes

Poret, N. (2015) · theses.fr (ABES) · doi:10.70675/4ce9f7d1z4df8z45f6z898ez9f885ed6fb5a

The Development Of A Novel Chimeric Antigen Receptor Specific For Syndecan-1

Berinstein, E. M. (2016) · TSpace (University of Toronto)

Updates and rationale of clinical trials in multiple myeloma

Branagan, A. R., Lei, M. M., Tracey, C., & Raje, N. S. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.59

Preliminary crystallographic study of CD38 in complex with isatuximab, an FDA-approved antibody drug for treating multiple myeloma

Lee, H. T., Kim, Y.-J., Park, U. B., Jeong, T. J., & Heo, Y.-S. (2020) · Korean Society for Structural Biology · doi:10.34184/kssb.2020.8.4.83

New Targeted Therapies for Multiple Myeloma Under Clinical Investigation

Dix, C. H. K., & Bryant, C. E. (2021) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-73440-4_9

SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies

Park, P. U., Blanc, V., Deckert, J., Lejeune, P., Bartle, L. M., Skaletskaya, A., Mayo, M., Zhang, C., Wetzel, M.-C., Tavares, D., et al. (2008) · Blood · doi:10.1182/blood.v112.11.2756.2756 · Cited by 6

Abstract 5469: SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma.

Hann, B. C., Cai, T., Wang, D., Hom, Y. K., Aftab, B. T., Martin, T. G., & Wolf, J. L. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5469 · Cited by 2

Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies.

Wetzel, M.-C., Nicolazzi, C., Vallée, F., Deckert, J., Dumontet, C., Pleșa, A., Kannt, A., Mikol, V., Chiron, M., Vincent, L., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4735 · Cited by 3

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Peipp, M., de Weers, M., Beyer, T. D., Repp, R., Parren, P. W. H. I., Valerius, T., & van de Winkel, J. G. J. (2005) · Blood · doi:10.1182/blood.v106.11.3377.3377 · Cited by 1

Abstract #2048: SAR650984, a humanized anti-CD38 antibody, shows potent in vitro activity by multiple mechanisms against various hematologic tumor cell lines.

Deckert, J., Yi, Y. W., Chicklas, S., Mayo, M., Chittenden, T. W., & Park, P. U. (2009) · Cancer Research